Updates -Smoldering Multiple #Myeloma from ASH 2025 | Rahul Banerjee, MD, FACP

Anito-cel (a BCMA CAR-T) : Shows No Cases of Delayed Neurotoxicity | Natalie Callander, MD

Anito-cel (a BCMA CAR-T) : Shows No Cases of Delayed Neurotoxicity | Natalie Callander, MD

S100A8 -a new target to prevent T cell exhaustion BsAbs in myeloma | Adolfo Aleman, PhD

S100A8 -a new target to prevent T cell exhaustion BsAbs in myeloma | Adolfo Aleman, PhD

Fewer Bone Marrow Biopsies? Using Blood & Whole Genome Sequencing | Chrissy Baker, MSc

Fewer Bone Marrow Biopsies? Using Blood & Whole Genome Sequencing | Chrissy Baker, MSc

Making CAR-T Cells inside the body? inMMyCAR Trial Insights | Natalie Callander, MD

Making CAR-T Cells inside the body? inMMyCAR Trial Insights | Natalie Callander, MD

Does MGIP represent the earliest stage of myeloma? | Sungjae Kim, PhD

Does MGIP represent the earliest stage of myeloma? | Sungjae Kim, PhD

Etentamig in patients with relapsed refractory amyloidosis | Rajshekhar Chakraborty, MD

Etentamig in patients with relapsed refractory amyloidosis | Rajshekhar Chakraborty, MD

Update on Arlo-Cel, a GPRC5D CAR-T, in RRMM | Ciara Freeman, MD, PhD

Update on Arlo-Cel, a GPRC5D CAR-T, in RRMM | Ciara Freeman, MD, PhD

AI Using Multimodal Datasets to Predict Response to CAR-T Treatment | Ciara Freeman, MD, PhD

AI Using Multimodal Datasets to Predict Response to CAR-T Treatment | Ciara Freeman, MD, PhD

Prophylactic Tocilizumab to Prevent CRS During Bispecific Step-up Dosing | Astrid Torpe, MD

Prophylactic Tocilizumab to Prevent CRS During Bispecific Step-up Dosing | Astrid Torpe, MD